Literature DB >> 1770133

Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups.

R H Asch1, H P Li, J P Balmaceda, L N Weckstein, S C Stone.   

Abstract

In a retrospective analysis of 637 cycles of ovarian stimulation and transvaginal follicular aspiration for various assisted reproductive technologies, severe ovarian hyperstimulation syndrome (SOH) occurred in six (0.94%) cycles. The patients at a high risk of developing SOH in cycles of assisted reproduction were those who had excessive serum oestradiol levels on the day of human chorionic gonadotrophin (HCG) administration (oestradiol greater than 6000 pg/ml; 38% SOH) and a high number of oocytes obtained (greater than 30 oocytes; 23% SOH). In those patients with both oestradiol greater than 6000 pg/ml on the day of HCG administration and greater than 30 eggs retrieved, the chance of developing SOH was 80%. The higher the serum oestradiol levels and the more eggs retrieved, the higher the pregnancy rates observed. High oestradiol level did not appear to have a detrimental effect on pregnancy rates and outcome. Furthermore, our results are not consistent with suggestions that the addition of gonadotrophin-releasing hormone agonist to ovarian stimulation protocols, follicular aspiration and/or luteal support with progesterone may reduce the incidence of ovarian hyperstimulation syndrome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1770133     DOI: 10.1093/oxfordjournals.humrep.a137276

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  30 in total

1.  Preretrieval predictors of pregnancy in IVF.

Authors:  A J Duleba; N Hausman; E E Jones; D L Olive
Journal:  J Assist Reprod Genet       Date:  1997-04       Impact factor: 3.412

2.  Severe ovarian hyperstimulation syndrome after letrozole-gonadotropin stimulation: a case report.

Authors:  Jayeon Kim; Anne Z Steiner; Marc Fritz; Jennifer E Mersereau
Journal:  J Assist Reprod Genet       Date:  2011-11-17       Impact factor: 3.412

Review 3.  Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI).

Authors:  Irene Kwan; Siladitya Bhattacharya; Angela Kang; Andrea Woolner
Journal:  Cochrane Database Syst Rev       Date:  2014-08-24

4.  Prevention of ovarian hyperstimulation syndrome by early aspiration of small follicles in hyper-responsive patients with polycystic ovaries during assisted reproductive treatment cycles.

Authors:  Oluseye A Oyawoye; Bina Chander; Jocelyn Hunter; Ahmed Abdel Gadir
Journal:  MedGenMed       Date:  2005-08-16

5.  Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome.

Authors:  T Tomazevic; H Meden-Vrtovec
Journal:  J Assist Reprod Genet       Date:  1996-04       Impact factor: 3.412

6.  Continuous ascitic recirculation in severe ovarian hyperstimulation syndrome.

Authors:  D H Beck; S Massey; B L Taylor; G B Smith
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

7.  Follicular aspiration does not protect against the development of ovarian hyperstimulation syndrome.

Authors:  M A Aboulghar; R T Mansour; G I Serour; I Elattar; Y Amin
Journal:  J Assist Reprod Genet       Date:  1992-06       Impact factor: 3.412

8.  GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Ivy Maina; Clarisa Gracia; Anuja Dokras
Journal:  J Assist Reprod Genet       Date:  2016-06-27       Impact factor: 3.412

9.  Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome.

Authors:  E R Levin; G F Rosen; D L Cassidenti; B Yee; D Meldrum; A Wisot; A Pedram
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

10.  Comparison of follicular fluid and serum levels of Inhibin A and Inhibin B with calculated indices used as predictive markers of Ovarian Hyperstimulation Syndrome in IVF patients.

Authors:  Jiri Moos; Karel Rezabek; Vanda Filova; Martina Moosova; Jana Pavelkova; Jana Peknicova
Journal:  Reprod Biol Endocrinol       Date:  2009-08-24       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.